You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Recall of ventolin inhalers
Australia's medicines watchdog, the Therapeutic Goods Administration (TGA), announced today that the pharmaceutical company, GlaxoSmithKline, (GSK) has voluntarily recalled what remains of a batch of 63,000 Ventolin 100mcg CFC-Free Inhalers because of a potential faulty valve.
GSK believes that the likelihood of a consumer receiving an inhaler with a faulty value is low due to the small number of inhalers affected. However, as Ventolin is used for acute relief of asthma and chronic obstructive airways disease symptoms, there is a potential for the patient's condition to worsen if they cannot use their Ventolin inhaler when required.
The Ventolin that is being recalled has been on the Australian market since May 2003 and it is likely that most of the stock has been purchased and used.
People who use Ventolin inhalers are encouraged to check the batch number of their inhaler by pulling out the canister from the tube and locating the batch number on the bottom of the canister label.
If the batch number corresponds with Batch Number KN6261, consumers are advised to return the inhaler to the place of purchase for exchange at no cost.
It is, however, important that consumers not cease using any respiratory medication without consulting their medical practitioner first.
Recall advertisements will feature in metropolitan newspapers tomorrow.
For further information call the Ventolin Customer Line on 1800 009 395
Media contact: John Noble, Media Adviser, TGA 0413 890 241